Training grant in hemostasis and thrombosis

项目摘要/摘要 宾夕法尼亚大学(UPenn)和费城儿童医院(CHOP)指导了一项 NHLBI赞助的T32培训补助金，支持以下相关领域的博士后和博士后培训 过去20年的止血和血栓形成。该计划的目标是让这些受训人员为 在血液科学中的职业生涯，作为成功的研究人员，在与止血和 血栓形成包括学术界、研究机构和行业(制药/生物技术)。宾夕法尼亚大学和查普大学 对基础、翻译和临床感兴趣的全国最大的研究人员集中之一 研究重点是揭示与止血相关的新机制见解和治疗干预措施 和血栓形成。我们招募了31名有才华的教职员工，其中8人是年轻教员，10人是年轻教员 其中包括女性，以指导和培训我们的学生/研究员，并为他们提供综合的、协作的 经验，以确保对止血和血栓形成感兴趣的科学家的丰富管道。除了……之外 严格的科学训练(具体目标1)，我们的计划有密集的止血和血栓形成教学 课程(七个独特组成部分；具体目标2)，并促进关键核心能力的发展 例如负责任地进行研究、沟通/写作技能、专业精神、管理技能 以及职业发展工具，都得到了宾夕法尼亚大学和CHOP(具体目标3)丰富的基础设施的支持。 罗德尼·卡米雷博士是项目主任，道格拉斯·辛斯博士是联席主任，他们监督所有 培训计划的各个方面。此外，该方案还收到了来自五个内部部门和三个部门的关键反馈 外部咨询委员会成员，以及协助该计划的成功的前T32校友 主任监督受训人员的进度(具体目标4)。自上一个资金周期以来，我们修改了 受训人员总数为2名博士后和4名博士后，以更好地捕捉最优秀和最聪明的人才 学生/研究员与我们的培训师一起工作，培训师来自宾夕法尼亚大学和CHOP的六个系/部门 以及宾夕法尼亚大学的五个不同的毕业生团体。自2000年启动以来，该项目培养了32名博士后 (40%为女性)和36名博士后科学家(48%为女性)，其中12%为代表不足的少数民族。完毕 我们75%的实习生仍然从事以研究为主的职业，我们博士后和博士后的比例约为51% 学术界的受训人员--主要是研究，约27%在制药/生物技术部门--主要是研究，有 其余(21%)从事与研究相关的职业，如科学作家/顾问。我们相信这个项目，有 一个非常丰富和互动的教职员工群体，提供了令人兴奋的研究机会 与强大的教学和指导计划相结合，专注于当今和正在出现的新挑战 止血和血栓形成。我们希望有机会培养那些将成为重要人物的人 他对这些研究领域做出了贡献，并将成为止血和血栓形成领域的领导者。

PROJECT SUMMARY/ABSTRACT The University of Pennsylvania (UPENN) and Children's Hospital of Philadelphia (CHOP) have directed an NHLBI-sponsored T32 training grant supporting pre- and postdoctoral trainees in the interrelated areas of hemostasis and thrombosis for the past 20 years. The goal of the program is to prepare these trainees for careers in the blood sciences as successful investigators working in the areas related to hemostasis and thrombosis that include academia, research institutes, and industry (pharma/biotech). UPENN and CHOP have one of the largest concentration of investigators in the country interested in basic, translational, and clinical research focused on uncovering new mechanistic insights and therapeutic interventions related to hemostasis and thrombosis. We draw upon 31 of these talented faculty members, eight of which are young trainers and 10 of which are female, to mentor and train our students/fellows and provide them with an integrated, collaborative experience to ensure a rich pipeline of scientists interested in hemostasis and thrombosis. In addition to rigorous scientific training (specific aim 1), our program has an intensive hemostasis and thrombosis didactic curriculum (seven unique components; specific aim 2) and fosters development of key core competencies such as responsible conduct of research, communication/writing skills, professionalism, management skills, and career development tools all supported by the rich infrastructure at UPENN and CHOP (specific aim 3). Dr. Rodney Camire is the Program Director and Dr. Douglas Cines is the Co-Director and they oversee all aspects of the training program. Further, the program receives critical feedback from five Internal and three External Advisory Committee members, along with successful former T32 alumni, who assist the Program Director to monitor the progress of the trainees (specific aim 4). Since the last funding cycle, we modified the total number of trainees to 2 predocs and 4 postdocs to better capture the best and brightest available students/fellows working with our trainers who are drawn from six Departments/Division at UPENN and CHOP and five different graduate groups at UPENN. Since its inception in 2000, the program trained 32 predoctoral (40% female) and 36 postdoctoral scientists (48% female) 12% of which are underrepresented minorities. Over 75% of our trainees remain in careers which are primarily research, with ~51% of our pre- and postdoctoral trainees in academia-primarily research, ~27% in the pharmaceutical/biotech sector-primarily research, with the remaining (21%) in research-related careers as scientific writers/consultants. We believe this program, with an extraordinarily rich and interactive group of faculty members, provides exciting research opportunities combined with strong didactic and mentoring programs focused on todays and emerging new challenges in hemostasis and thrombosis. We hope to have the opportunity to train individuals who will make important contributions to these areas of research and will become leaders in the field of hemostasis and thrombosis.